PT - JOURNAL ARTICLE AU - Philippe Gautret AU - Jean-Christophe Lagier AU - Philippe Parola AU - Van Thuan Hoang AU - Line Meddeb AU - Morgane Mailhe AU - Barbara Doudier AU - Johan Courjon AU - Valérie Giordanengo AU - Vera Esteves Vieira AU - Hervé Tissot Dupont AU - Stéphane Honoré AU - Philippe Colson AU - Eric Chabrière AU - Bernard La Scola AU - Jean-Marc Rolain AU - Philippe Brouqui AU - Didier Raoult TI - Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial AID - 10.1101/2020.03.16.20037135 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.16.20037135 4099 - http://medrxiv.org/content/early/2020/03/20/2020.03.16.20037135.short 4100 - http://medrxiv.org/content/early/2020/03/20/2020.03.16.20037135.full AB - Background Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads.Patients and methods Patients were included in a single arm protocol to receive 600mg of hydroxychloroquine daily and their viral load in nasal swabs was tested daily. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point.Results Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination.Conclusion Hydroxychloroquine is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis clinical trial was approved by the French National Agency for Drug safety (ANSM) (2020-000890-25) and to the French Ethic Committee (CPP Ile de France) (20.02.28.99113) for reviewing and approved on 5th and 6th March, 2020, respectively. This trial is registered with EU Clinical trials register number 2020-000890-25.Funding StatementThis work was supported by the French Government under the « Investissements d’avenir » (Investments for the Future) program managed by the Agence Nationale de la Recherche (ANR, fr: National Agency for Research), (reference: Méditerranée Infection 10-IAHU-03)Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available on request